VEGF-C is required for intestinal lymphatic vessel maintenance and lipid absorption

Nurmi, Harri

2015-11


http://hdl.handle.net/10138/161934
https://doi.org/10.15252/emmm.201505731

Downloaded from Helda, University of Helsinki institutional repository.
This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail.
Please cite the original version.
VEGF-C is required for intestinal lymphatic vessel maintenance and lipid absorption

Harri Nurmi, Pipsa Saharinen, Georgia Zarkada, Wei Zheng, Marius R Robciuc† & Kari Alitalo*,†

Abstract

Vascular endothelial growth factor C (VEGF-C) binding to its tyrosine kinase receptor VEGFR-3 drives lymphatic vessel growth during development and in pathological processes. Although the VEGF-C/VEGFR-3 pathway provides a target for treatment of cancer and lymphedema, the physiological functions of VEGF-C in adult vasculature are unknown. We show here that VEGF-C is necessary for perinatal lymphangiogenesis, but required for adult lymphatic vessel maintenance only in the intestine. Following Vegfc gene deletion in adult mice, the intestinal lymphatic vessels, including the lacteal vessels, underwent gradual atrophy, which was aggravated when also Vegfd was deleted. VEGF-C was expressed by a subset of smooth muscle cells adjacent to the lacteals in the villus and in the intestinal wall. The Vegfc-deleted mice showed defective lipid absorption and increased fecal excretion of dietary cholesterol and fatty acids. When fed a high-fat diet, the Vegfc-deficient mice were resistant to obesity and had improved glucose metabolism. Our findings indicate that the lymphangiogenic growth factors provide trophic and dynamic regulation of the intestinal lymphatic vasculature, which could be especially important in the dietary regulation of adiposity and cholesterol metabolism.

Keywords cholesterol; lipid absorption; lymphatic vasculature; obesity; VEGF-C

Subject Categories Development & Differentiation; Vascular Biology & Angiogenesis

DOI 10.15252/emmm.201505731 | Received 7 August 2015 | Revised 22 September 2015 | Accepted 25 September 2015 | Published online 12 October 2015


Introduction

Lymphatic vessels regulate tissue fluid homeostasis, immune cell trafficking, and dietary fat absorption, and their malfunction leads to chronic edema and impaired immune responses (Cueni & Detmar, 2008; Alitalo, 2011; Koltowska et al., 2013). Lymphangiogenesis occurs during pathological processes such as inflammation and tumor metastasis and inhibitors of lymphangiogenic growth factors and their receptors are currently in clinical trials in human cancer patients (Alitalo, 2011). The development of the lymphatic vasculature is guided primarily by VEGF-C-mediated activation of VEGFR-3, which is the main VEGF receptor expressed by lymphatic endothelial cells (Makinen et al., 2001; Karkkainen et al., 2004). In the absence of VEGF-C, the development of lymphatic vessels is arrested during their initial sprouting from embryonic veins (Karkkainen et al., 2004). VEGF-D, the second VEGF-R-3 ligand, cannot compensate for the absence of VEGF-C during development, but it induces lymphangiogenesis when overexpressed and its deletion during development results in mild lymphatic vessel atrophy in the skin (Rissanen et al., 2003; Karkkainen et al., 2004; Alitalo, 2011; Paquet-Fifield et al., 2013; Astin et al., 2014).

During the postnatal period, the lymphatic vessels continue to expand, and in the intestine, the lacteal vessels grow into the intestinal villi to facilitate lipid absorption from the fat-rich milk (Kim et al., 2007). Lipid absorption allowed Gaspare Aselli to discover lymphatic vessels by their content of milky fluid in the 17th century (Dixon, 2010). Recent studies have shown that the lacteal vessels are actively involved in lipid transport from the small intestinal epithelium to the lymphatic system and further to the blood circulation, although the detailed mechanisms have not been elucidated (Dixon, 2010). In several genetic mouse models of impaired lymphatic development, including Vegfr3 and Vegfc hypomorphic mice, and Chy mice that have a missense point mutation in Vegfr3, lipid-rich chylous ascites develops after birth but resolves before weaning (Karkkainen et al., 2001, 2004; Haiko et al., 2008). However, the possible function of lymphangiogenic growth factors in the normally developed adult intestine is not known.

Here we have studied the role of VEGF-C in lymphatic vessel growth, maintenance, and function in neonatal and adult mice by using a mouse model that allows effective Vegfc gene deletion by the Cre-Lox system (Aspelund et al., 2014). We demonstrate that VEGF-C has a crucial role in the maintenance of the intestinal lymphatic vessels and dietary fat absorption.

Results and Discussion

Vegfc gene deletion arrests lymphatic vessel growth in the developing intestine

In Vegfc gene-deleted embryos, lymphatic vessel sprouting from the major embryonic veins at embryonic day (E) 10.5 is arrested and...
the embryos die between E15.5 and E17.5 (Karkkainen et al., 2004). To study how the loss of VEGF-C affects lymphatic vessel development during the last trimester of fetal development, we crossed the Vegfc<sup>lox/lox</sup> mice (Aspelund et al., 2014) with mice expressing the universal deletor R26Cre-ERT2 (Ventura et al., 2007). To delete Vegfc in the R26Cre-ERT2;Vegfc<sup>lox/lox</sup> embryos, pregnant females were injected with 4-OH tamoxifen at E12.5 and E13.5. Analysis at E18.5 indicated that the Vegfc-deleted (VCiΔR26) embryos lack mesenteric lymphatic vessels either completely (data not shown) or exhibit lymphatic vessel fragments and blind-ended lymphatic stubs that extend toward the intestinal wall (Fig 1A and B). Deletion of Vegfc at E14.5 blocked the maturation of the mesenteric collecting lymphatic vessels. The developing vessels lacked valves and were much thinner than in the wild-type (WT) Vegfc<sup>lox/lox</sup> embryos.

**Figure 1.** VEGF-C is required for lymphatic vessel growth in the developing intestine and for the intestinal lymphatic vessel maintenance in adult mice. Mice received tamoxifen as indicated in the figure. Immunofluorescence analyses from the intestine were performed in (A–H) embryos, (I–L) pups, and (M–U) adults.

A–D Mesenteric blood (PECAM1, red) and lymphatic vessels (LYVE1, green; PROX1, gray). Asterisks indicate lymphatic valves, arrow indicates a lymphatic vessel stub, and arrowhead indicates an isolated lymphatic vessel fragment.

E–H Blood vessels (PECAM1, green) and lymphatic vessels (VEGFR-3, red) in the small intestinal wall.

I, J Detection of chylous ascites (arrows) in the VCiΔR26 mice at P6.

K, L LYVE1 staining of intestinal lymphatic vessels at P6.

M–T LYVE1 staining of lymphatic vessels in the intestinal wall in adult mice. Genotypes and deletion lengths are indicated in (U).

U Quantification of LYVE1 areas in (M–T). Length of the ΔVegfc gene deletion is indicated in months (mo), and Vegfd indicates the VEGF-D genotype. Data are represented as mean ± SEM. Significant differences were determined using one-way ANOVA and Bonferroni post hoc analysis compared to WT intestine represented in (M). *P = 0.003, **P = 0.001, ***P = 0.0008, *P = 0.0002, 2P = 0.0001.

Data information: Scale bars: 200 μm in (A–H) and 400 μm in (K–T). n = 25 (M); 5 (N); 7 (O); 6 (Q); 5 (R); 6 (S); 3 (T).
ligand for VEGFR-3, cannot compensate for the lack of VEGF-C on VEGF-C/VEGFR-3 signaling, while VEGF-D, the other known
and then progressed to the lymphatic network in the intestinal wall. (Fig S2B). Thus, the lymphatic vessel atrophy started from lacteals
was effectively deleted for 6 months, whereas the blood
vasculature in the adult VCi
H). The
lymphatic vessels of the intestinal wall were not altered, suggesting that VEGF-C can signal via
S4A and B). However, lymphatic vessel density in the intestinal
lacteal vessel regression, similar to VEGF-C deletion (Appendix Fig S4A and B). However, lymphatic vessel density in the intestinal
vasculature in the adult intestine. Previous work from our laboratory showed that VEGF-C is expressed in arterial smooth muscle cells (SMCs)
in both in mice and humans (Partanen et al, 2000; Paavonen et al, 2002; Karkkainen et al, 2004). To define the cells expressing
VEGF-C and its receptors, we performed β-Gal staining of intesti-
nes from Vegfc/LacZ (Karkkainen et al, 2004), Vegfr3/LacZ (Du-
mont et al, 1998), and Vegfr2/LacZ (Shalaby et al, 1995) mice. VEGF-C staining in the villi was weak in comparison with VEGFR-3
and VEGFR-2 stainings, in lymphatic and blood vessels, respec-
tively (Fig 2A and B). Higher resolution analysis combined with
immunohistochemistry demonstrated VEGF-C expression in SMCs,
in the inner circular muscle layer of the intestinal wall, in arterial
smooth muscle, and in a subset of the SMC fibers in the villus
(Fig 2C). In the villi, the VEGF-C β-Gal signal was most prominent
adjacent to the LYVE1-counterstained lymphatic vessels (Fig 2D).
The intestinal wall of the Vegfc/LacZ mice showed a prominent
arterial β-Gal staining pattern, which was further analyzed by
PECAM-1 counterstaining of cross sections (Fig 2E), which
confirmed VEGF-C expression in the arterial SMCs. Whole-mount
confocal microscopy showed a close contact between the lacteal
vessels and the SMC fibers in the basal part of the villus where
also β-Gal staining of VEGF-C was detected (Fig 2D and F). These
results suggest that SMCs in the villi and in the intestinal wall
provide an important source for VEGF-C, which is required to
maintain the lymphatic vessel architecture in the intestine. It
should be noted that SMC contractility in the villi has been
suggested to be important for dietary lipid absorption and that
VEGF-C can induce contraction of the SMCs around the collecting
lymphatic vessels in normal and pathological conditions (Hosoya-
mada & Sakai, 2005, 2007; Breslin et al, 2007; Gogineni et al,
2013).

To determine whether the effect of VEGF-C on intestinal
lymphatic vessels is dependent on VEGFR-3, we analyzed the
Rosa26CreERT2;Vegfr3<sup>fox/fox</sup> (R3iΔR26) mouse model (Haiko et al, 2008). As expected, deletion of Vegfr3 for 3 months induced
lacteal vessel regression, similar to VEGF-C deletion (Appendix Fig
S4A and B). However, lymphatic vessel density in the intestinal
wall was not altered, suggesting that VEGF-C can signal via
VEGFR-2 to stabilize the lymphatic plexus. We have previously
shown that the tyrosine kinase inhibitor cediranib inhibits
lymphangiogenesis induced by adenoviral VEGF-C delivery into
adult mouse skin (Heckman et al, 2008). However, administration
of the tyrosine kinase inhibitor sunitinib at doses that block
VEGFR-2 and VEGFR-3 (K:< VEGFR-3 17 nM/VEGFR-2 9 nm)
(Falvre et al, 2007) had no effect on the lacteal vessels, although
sunitinib significantly reduced blood vessel density in the intestinal
villi (Appendix Fig S4C-E), in line with a previous report (Kamba
et al, 2006). Thus, lacteal vessels appear to be more resistant than
blood vessels in the intestinal villus toward VEGFR tyrosine kinase
inhibition.
Figure 2. Smooth muscle cells are the main source of VEGF-C in adult intestine.
A Overview of the small intestine cross section stained with nuclear red and highlighting the location of higher magnification images in (B–F); (I) for the entire villus and (II) for the villus base. β-Gal staining pattern of the villus in wild-type (Ctrl), Vegfc/LacZ (VC), Vegfr3/LacZ (VR-3), and Vegfr2/LacZ (VR-2) mice.
B Higher magnification images representing β-Gal staining of the villus base in Vegfc/LacZ mice.
C Vegfc/LacZ β-Gal staining reaction with smooth muscle actin (SMA) peroxidase staining.
D Vegfc/LacZ β-Gal staining and LYVE1 peroxidase staining.
E Surface image of Vegfc/LacZ β-Gal-stained intestine (left) and cross section counterstaining with PECAM1 (right).
F Immunofluorescence staining of lacteal lymphatic vessel (LYVE1), blood capillaries (PECAM1), and smooth muscle cells (SMA).

Data information: Arrows indicate the VEGF-C expression in arterial SMC, arrowheads indicate the VEGF-C expression in SMC fibers in the villus, and asterisks highlight the VEGF-C expression in circular smooth muscle cell layer of the intestinal wall. Scale bars: 50 μm, except (C) inset 25 μm.
Figure 3. Intestinal lymphatic vessel regression leads to impaired lipid absorption and resistance to diet-induced obesity.

Two-month-old mice received tamoxifen and were fed on high-fat diet (HFD) for seven weeks before analysis.

A Body weight change during seven weeks of HFD, expressed as average fold change in comparison with the starting weight. \( n = 16, \) WT; \( n = 6, \) Vegfd\(^{-/-}\); \( n = 16, \) VCI\(\Delta R26\).

B Body weight comparisons at seven weeks of HFD. Significant differences were determined using one-way ANOVA and Bonferroni post hoc analysis compared to WT. *\( P = 0.004; \) **\( P = 0.003. \) \( n = 16, \) WT; \( n = 6, \) Vegfd\(^{-/-}\); \( n = 16, \) VCI\(\Delta R26\); \( n = 5, \) Vegfd\(^{-/-}\); VCI\(\Delta R26\).

C Glucose tolerance test (GTT) after six weeks of HFD. Significant differences were determined using unpaired two-tailed \( t \)-test. *\( P = 0.014; \) **\( P = 0.041. \) \( n = 5, \) WT; \( n = 6, \) VCI\(\Delta R26\).

D Total fat weight, fat percentage from body composition measurements after six weeks of HFD, and weights of visceral fat (VF) and subcutaneous fat (SF) at the time of necropsy. Significant differences were determined using unpaired two-tailed \( t \)-test. *\( P = 0.006; \) **\( P = 0.001; \) #\( P = 0.008; \) §\( P = 0.006. \) \( n = 4 \) in each group.

E Food consumption during the fifth week of HFD. \( n = 9, \) WT; \( n = 10, \) VCI\(\Delta R26\).

F Whole-mount immunofluorescence staining of blood (PECAM1, red) and lymphatic vessels (LYVE1, green) in intestinal villi and intestinal wall.

G Quantification of the lacteal and villus length (solid and striped color bars, respectively) and the intestinal wall LYVE1\(^{+}\) area percentage from images represented in (F). Significant differences were determined using unpaired two-tailed \( t \)-test. *\( P = 0.002; \) **\( P = 0.0007. \) \( n = 5, \) WT; \( n = 6, \) VCI\(\Delta R26\).

H Free fatty acid (FFA) and cholesterol measurements from the feces after six weeks of HFD. Significant differences were determined using unpaired two-tailed \( t \)-test. *\( P = 0.001; \) **\( P = 0.007. \) \( n = 5, \) WT; \( n = 6, \) VCI\(\Delta R26\).

Data information: Scale bars: 100 \( \mu \)m (villi) and 300 \( \mu \)m (intestinal wall). Data are represented as mean ± SEM.
**Vegfc deletion reduces lipid absorption, inducing resistance to diet-induced obesity**

To determine whether VEGF-C is important for lipid absorption by the intestinal lymphatic vessels, we performed an oral fat tolerance test in mice in which VEGF-C had been deleted 3 months earlier. The clearance of triglycerides from plasma was blocked by injection of Triton WR 1339, an inhibitor of lipoprotein lipase activity (Otway & Robinson, 1967). Analysis of triglyceride levels in serum after the administration of an oil bolus showed that the VCiAR26 mice have impaired lipid absorption when compared to WT mice (Appendix Fig S5A). Although these results correlate with the lacteal regression, we cannot exclude the involvement of possible other effects of Vegfc deletion.

We further studied whether the reduction in dietary lipid absorption observed in the VCiAR26 mice has an impact on diet-induced obesity in mice fed high-fat diet (HFD). Initial experiments in the 129SV/C57Bl/6J mixed genetic background did not reveal major differences in body weight, but indicated that the VCiAR26 mice have an improved glucose metabolism compared to WT mice (Appendix Fig S5B and C). Interestingly, in the mixed background, the Vegfc-deleted mice had reduced serum cholesterol levels, whereas fecal cholesterol and free fatty acid (FFA) levels were increased in the VCiAR26 mice, indicating impaired dietary lipid absorption (Appendix Fig S5D). We further performed HFD feeding experiments in the pure C57Bl/6J background, an established model of diet-induced obesity. We deleted Vegfc in 8-week-old male mice and started HFD feeding 4 weeks later. The VCiAR26 mice gained significantly less weight and had better glucose tolerance than their WT littermates, independently of concurrent Vegfd deletion (Fig 3A–C and Appendix Fig S5E and F). At necropsy after HFD, very low amounts of chyle were detected in one out of 16 Vegfc-deleted mice and in two out of five Vegfc plus Vegfd-deleted mice, indicating mild lymphatic leakage. Body composition analysis showed that the VCiAR26 mice had a significant reduction in total fat weight and fat percentage, but no changes in lean weight in comparison with WT littermates (Fig 3D and Appendix Fig S5G). The changes in fat accumulation could not be explained by reduced caloric intake, since food consumption was similar between the VCiAR26 and WT mice (Fig 3E). As expected on the basis of our results from the mixed background, Vegfc deletion induced intestinal lymphatic vessel atrophy and increased lipid excretion into the feces also in the C57Bl/6J background (Fig 3F–H). No difference in body weight was observed between WT and Vegfc-deleted mice on regular diet in which the majority of calories are derived from carbohydrate. This further indicates that the reduced body weight of the Vegfc-deleted mice on HFD is a result of reduced dietary lipid absorption.

Use of the newly established Vegfc gene targeted mouse model allowed us to determine the effect of chronic VEGF-C deficiency in adult mice, where lymphatic vasculature is normally in a quiescent state (Aspelund et al, 2014). The results of this study show that intestinal lymphatic vessels in adults require trophic signals from VEGF-C and that Vegfd can only partially compensate for the loss of VEGF-C to maintain their structure and function. The unexpected finding that VEGF-C blockade affects only intestinal lymphatic vasculature and lipid absorption may provide new therapeutic opportunities. The specific VEGF-C/VEGFR-3 inhibitors that are currently in phase 1 clinical trials for cancer treatment could provide additional benefit for the treatment of obesity and cardiovascular disease by reducing the absorption of excess dietary lipids.

Further studies should address lacteal vessel atrophy and dietary fat absorption in clinical trials employing VEGF-C/VEGFR-3 blocking therapeutics.

**Materials and Methods**

**Study approval**

National Animal Experiment Board in Finland approved all experiments involving the use of mice.

**Mice and tissues**

The mouse lines Vegfcfl/fl (Aspelund et al, 2014), Vegfr3fl/fl (Haiko et al, 2008), Rosa26-CreERT2 (Ventura et al, 2007), Vegfd (Baldwin et al, 2005), Vegfc/LacZ (Karkkainen et al, 2004), Vegfr3/LacZ (Dumont et al, 1998), and Vegfr2/LacZ (Shalaby et al, 1995) have been described previously. We used VCiAR26 mice in the mixed C57Bl/6J and 129SV background or after backcrossing to the C57Bl/6J strain for at least 7 generations. For induction of Cre-mediated recombination in embryos, the mother was injected at the indicated days with two consecutive intragastric doses of 4-OH tamoxifen (4-OHT) (Sigma) (25 mg/ml dissolved in 100 μl ethanol/olive oil). In the neonatal VCiAR26 or WT mice, the Cre-mediated recombination was induced between P1 and P4 by daily intragastric administration of 2 μl 4-OHT (25 mg/ml dissolved in ethanol). Recombination in adult mice (7–8 weeks old) was done by intragastric tamoxifen (Sigma, dissolved in corn oil at 2 mg/ml, 100 μl) administration during five consecutive days. Detailed animal experiment information can be found in the Appendix Supplementary Materials and Methods.

**Statistics**

Quantitative data were compared between groups by two-tailed unpaired t-test or one-way ANOVA followed by Bonferroni post hoc test for multiple comparisons. Values are expressed as mean ± SEM. P-value < 0.05 was considered significant.

**Expanded View** for this article is available online: http://emmm.embopress.org

**Acknowledgements**

We thank Jarmo Koponen, Essi Salminen, Maija Atuegwu, Mari Jokinen, Tapio Tainola, and Kirsi Mänttäri for technical assistance, the personnel of the Biomedicum Imaging Unit for microscopy service and the Laboratory Animal Center of the University of Helsinki for animal housing. This study was supported in part by the Leducq Transatlantic Network of Excellence in Lymph Vessels in Obesity and Cardiovascular Disease (grant no: 11CV003), the Marie Curie ITN Vessel consortium (grant no: 317250) of the Seventh Framework Program of European Union, Academy of Finland Centre of Excellence in Translational Cancer Biology 2014–2019 (grant no: 271845), the European Research Council (ERC-2010-AdG-268804), the Finnish Cancer Research Organizations, the Sigrid Juselius Foundation, and by the Biomedicum Helsinki Foundation and Ida Montin Foundation (to H.N.).
The paper explained

Problem

Specific VEGF-C/VEGFR-3 inhibitors are currently in phase I clinical trials for cancer treatment, but the effects of long-term inhibition of these pathways in adults are still incompletely known. Preclinical long-term follow-up studies of VEGF-C/VEGFR-3 signaling deficiency are now possible by using the novel mouse model that allows effective Vegfc gene deletion by the Cre-Lox system. This eliminates the confounding effects of developmental defects observed in previous mouse models.

Results

The mouse model used in this study allowed effective, timed, and long-lasting gene deletion of Vegfc. Surprisingly, in adults with normally developed lymphatic system, Vegfc was required only for the maintenance of intestinal lymphatic vessel structure and function. Regression of lymphatic vessels in the intestine induced by Vegfc deletion had no effects on animal welfare but protected the mice from the obesogenic effect of excessive dietary lipid uptake.

Impact

Long-term inhibition of VEGF-C/VEGFR-3 is very well tolerated in animal models. VEGF-C blockade induces atrophy of intestinal lymphatic vessels and inhibits dietary lipid absorption, which could provide new therapeutic opportunities for the treatment of obesity and cardiovascular diseases.

Author contributions

HN and MRR designed and performed experiments, data acquisition, analysis and interpretation of data, and wrote the manuscript; PS designed and produced the VClAR26 mice; GZ and W2 performed experiments; and KA designed experiments, conducted scientific direction, and wrote the manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

References

factor-d modulates caliber and function of initial lymphatics in the dermis. J Invest Dermatol 133: 2074 – 2084


License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.